Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01

Bibliography

• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343–9
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431(7006):371-8
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Crooke ST. Progress in antisense technology: the end of the beginning. Methods Enzymol 2000;313:3-45
   PubMed Web of Science ®Google Scholar
• Muntoni F, Wood MJ. Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 2011;10(8):621-37
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang L. A window onto siRNA delivery. Nat Biotechnol 2013;31(7):611-12
   PubMed Web of Science ®Google Scholar
• Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003;270(8):1628-44
   PubMedGoogle Scholar
• Grunweller A, Wyszko E, Bieber B, et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2’-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003;31(12):3185-93
   PubMed Web of Science ®Google Scholar
• Agrawal S, Zhao Q. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev 1998;8(2):135-9
   PubMedGoogle Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327(5962):198-201
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhang L, Zhang J, et al. Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation. FASEB J 2013;27(10):4017-26
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003;13(2):83-105
   PubMedGoogle Scholar
• Ueno Y, Kawada K, Naito T, et al. Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3’-termini. Bioorg Med Chem 2008;16(16):7698-704
   PubMed Web of Science ®Google Scholar
• Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005;33(1):439-47
   PubMed Web of Science ®Google Scholar
• Wu SY, Yang X, Gharpure KM, et al. 2’-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 2014;5:3459
   PubMed Web of Science ®Google Scholar
• Krieg A, Tonkinson J, Matson S, et al. Modification of antisense phosphodiester oligodeoxynucleotides by a 5’ cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci USA 1993;90:1048-52
   PubMed Web of Science ®Google Scholar
• Epa WR, Rong P, Bartlett PF, et al. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1998;8:489-98
   PubMedGoogle Scholar
• Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011;71:7608-16
   PubMed Web of Science ®Google Scholar
• Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 2013;587:1693-702
   PubMed Web of Science ®Google Scholar
• Madani F, Lindberg S, Langel U, et al. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011;2011:414729
   PubMedGoogle Scholar
• Martin I, Teixido M, Giralt E. Intracellular fate of peptide-mediated delivered cargoes. Curr Pharm Des 2013;19:2924-42
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-93
   PubMed Web of Science ®Google Scholar
• Pooga M, Hallbrink M, Zorko M, et al. Cell penetration by transportan. FASEB J 1998;12:67-77
   PubMed Web of Science ®Google Scholar
• Prater CE, Miller PS. 3’-methylphosphonate-modified oligo-2’-O-methylribonucleotides and their Tat peptide conjugates: uptake and stability in mouse fibroblasts in culture. Bioconjug Chem 2004;15:498-507
   PubMed Web of Science ®Google Scholar
• Reissmann S. Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci 2014;20:760-84
   PubMed Web of Science ®Google Scholar
• Ishihara T, Goto M, Kodera K, et al. Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides. Drug Deliv 2009;16:153-9
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014;66:110-16
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-14
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6
   PubMed Web of Science ®Google Scholar
• Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012;51:8529-33
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase I trial. Lancet 2014;383(9911):60-8
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819-29
   PubMed Web of Science ®Google Scholar
• Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-9
   PubMed Web of Science ®Google Scholar
• Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010;107:1864-9
   PubMed Web of Science ®Google Scholar
• Chono S, Li SD, Conwell CC, et al. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 2008;131:64-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650-6
   PubMed Web of Science ®Google Scholar
• Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983;70:124-31
   PubMedGoogle Scholar
• Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984;74:36-9
   PubMedGoogle Scholar
• Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7
   PubMed Web of Science ®Google Scholar
• Szebeni J, Bedocs P, Rozsnyay Z, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012;8:176-84
   PubMed Web of Science ®Google Scholar
• Verhoef JJ, Carpenter JF, Anchordoquy TJ, et al. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Hashimoto Y, Shimizu T, Mima Y, et al. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicol Appl Pharmacol 2014;277:30-8
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012;9:1319-23
   PubMed Web of Science ®Google Scholar
• Romberg B, Oussoren C, Snel CJ, et al. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochim Biophys Acta 2007;1768:737-43
   PubMed Web of Science ®Google Scholar
• Haeckel A, Appler F, Figge L, et al. XTEN-annexin A5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation. J Nucl Med 2014;55:508-14
   PubMed Web of Science ®Google Scholar
• Tari A, Gutierrez-Puente Y, Monaco G, et al. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol 2007;31:1243-50
   PubMed Web of Science ®Google Scholar
• Landen CNJr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-18
   PubMed Web of Science ®Google Scholar
• Verma A, Guha S, Diagaradjane P, et al. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008;14:2476-83
   PubMed Web of Science ®Google Scholar
• Zhang D, Tari A, Akar U, et al. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser(1) p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther 2010;9:3090-9
   PubMed Web of Science ®Google Scholar
• Tekedereli I, Alpay SN, Tavares CD, et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012;7(7):e41171
   PubMed Web of Science ®Google Scholar
• Mehta R, Lopez-Berestein G, Hopfer R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984;770:230-4
   PubMed Web of Science ®Google Scholar
• Juliano RL, Lopez-Berestein G, Hopfer R, et al. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci 1985;446:390-402
   PubMed Web of Science ®Google Scholar
• Mehta RT, Mehta K, Lopez-Berestein G, et al. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun 1985;47:429-33
   PubMed Web of Science ®Google Scholar
• Mehta RT, Hopfer RL, Gunner LA, et al. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 1987;31:1897-900
   PubMed Web of Science ®Google Scholar
• Mehta RT, Hopfer RL, McQueen T, et al. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987;31:1901-3
   PubMed Web of Science ®Google Scholar
• Lautersztain J, Perez-Soler R, Khokhar AR, et al. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II). Cancer Chemother Pharmacol 1986;18:93-7
   PubMed Web of Science ®Google Scholar
• Lowenstein E, Daly R, Batzer A, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992;70:431-42
   PubMed Web of Science ®Google Scholar
• Rozakis-Adcock M, McGlade J, Mbamalu G, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992;360:689-92
   PubMed Web of Science ®Google Scholar
• Olivier J, Raabe T, Henkemeyer M, et al. A Drosophila SH2-SH3 adaptor protein implicated in coupling the Sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange. Sos. Cell 1993;73:179-91
   PubMed Web of Science ®Google Scholar
• Rozakis Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363(6424):83-5
   PubMed Web of Science ®Google Scholar
• Gale NW, Kaplan S, Lowenstein EJ, et al. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 1993;363:88-92
   PubMed Web of Science ®Google Scholar
• Arvidsson AK, Rupp E, Nanberg E, et al. Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation. Mol Cell Biol 1994;14:6715-26
   PubMed Web of Science ®Google Scholar
• Skolnik E, Batzer A, Li N, et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993;260:1953-5
   PubMed Web of Science ®Google Scholar
• Lee CH, Li W, Nishimura R, et al. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci USA 1993;90:11713-17
   PubMed Web of Science ®Google Scholar
• Meyer S, LaBudda K, McGlade J, et al. Analysis of the role of the Shc and Grb2 proteins in signal transduction by the v-ErbB protein. Mol Cell Biol 1994;14:3253-62
   PubMed Web of Science ®Google Scholar
• Dikic I, Schlessinger J, Lax I. PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation. Curr Biol 1994;4:702-8
   PubMed Web of Science ®Google Scholar
• Pendergast A, Quilliam L, Cripe L, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993;75:175-85
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Hanks SK, Hunter T, et al. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994;372:786-91
   PubMed Web of Science ®Google Scholar
• Janes P, Daly R, deFazio A, et al. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994;9:3601-8
   PubMed Web of Science ®Google Scholar
• Sieh M, Batzer A, Schlessinger J, et al. GRB2 and phospholipase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation. Mol Cell Biol 1994;14:4435-42
   PubMed Web of Science ®Google Scholar
• Saleem A, Kharbanda S, Yuan ZM, et al. Monocyte colony-stimulating factor stimulates binding of phosphatidylinositol 3-kinase to Grb2.Sos complexes in human monocytes. J Biol Chem 1995;270:10380-3
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Dikic I, Sorokin A, et al. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996;16:977-89
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 1997;16:2634-45
   PubMedGoogle Scholar
• Riera L, Lasorsa E, Ambrogio C, et al. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem 2010;285:26441-50
   PubMed Web of Science ®Google Scholar
• Thomas SM, DeMarco M, D’Arcangelo G, et al. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell 1992;68:1031-40
   PubMed Web of Science ®Google Scholar
• Mitra G, Weber M, Stacey D. Multiple pathways for activation of MAP kinases. Cell Mol Biol Res 1993;39:517-23
   PubMedGoogle Scholar
• Gallego C, Gupta SK, Heasley LE, et al. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proc Natl Acad Sci USA 1992;89:7355-9
   PubMed Web of Science ®Google Scholar
• Williams NG, Paradis H, Agarwal S, et al. Raf-1 and p21v-ras cooperate in the activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1993;90:5772-6
   PubMed Web of Science ®Google Scholar
• Franke T, Yang S, Chan T, et al. The protein kinase encoded by the Akt protooncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36
   PubMed Web of Science ®Google Scholar
• Burgering B, Coffer P. Protein kinase B (c-Akt) in phosphatidylinositol 3-OH kinase signal transduction. Nature 1995;376:599-602
   PubMed Web of Science ®Google Scholar
• Datta K, Bellacosa A, Chan T, et al. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996;271:30835-9
   PubMed Web of Science ®Google Scholar
• Marte B, Rodriguez-Viciana P, Wennstrom S, et al. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997;7:63-70
   PubMed Web of Science ®Google Scholar
• Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, King-Underwood L. The Wilms tumour gene WT1 in leukaemia. Leuk Lymphoma 1997;27:207-20
   PubMed Web of Science ®Google Scholar
• Khwaja A, Rodriguez-Viciana P, Wennstrom S, et al. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997;16:2783-93
   PubMed Web of Science ®Google Scholar
• Chardin P, Camonis J, Gale N, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993;260:1338-43
   PubMed Web of Science ®Google Scholar
• McPherson PS, Czernik AJ, Chilcote TJ, et al. Interaction of Grb2 via its Src homology 3 domains with synaptic proteins including synapsin I. Proc Natl Acad Sci USA 1994;91:6486-90
   PubMed Web of Science ®Google Scholar
• Seedorf K, Kostka G, Lammers R, et al. Dynamin binds to SH3 domains of phospholipase C gamma and GRB-2. J Biol Chem 1994;269:16009-14
   PubMed Web of Science ®Google Scholar
• Tanaka S, Morishita T, Hashimoto Y, et al. C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci USA 1994;91:3443-7
   PubMed Web of Science ®Google Scholar
• Donovan JA, Wange RL, Langdon WY, et al. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor. J Biol Chem 1994;269:22921-4
   PubMed Web of Science ®Google Scholar
• Odai H, Sasaki K, Iwamatsu A, et al. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 1995;270:10800-5
   PubMed Web of Science ®Google Scholar
• Meisner H, Conway BR, Hartley D, et al. Interactions of Cbl with Grb2 and phosphatidylinositol 3’-kinase in activated Jurkat cells. Mol Cell Biol 1995;15:3571-8
   PubMed Web of Science ®Google Scholar
• Lepley R, Fitzpatrick F. 5-lipooxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J Biol Chem 1994;269:24163-8
   PubMed Web of Science ®Google Scholar
• Ohmichi M, Matuoka K, Takenawa T, et al. Growth factors differentially stimulate the phosphorylation of Shc proteins and their association with Grb2 in PC-12 pheochromocytoma cells. J Biol Chem 1994;269:1143-8
   PubMed Web of Science ®Google Scholar
• Wang J, Auger K, Jarvis L, et al. Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 1995;270:12774-80
   PubMed Web of Science ®Google Scholar
• Holgado-Madruga M, Emlet D, Moscatello D, et al. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 1996;379:560-4
   PubMed Web of Science ®Google Scholar
• Robinson A, Gibbins J, Rodriguez-Linares B, et al. Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking. Blood 1996;88:522-30
   PubMed Web of Science ®Google Scholar
• Tortora G, Damiano V, Bianco C, et al. The RIa subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 1997;14:923-8
   PubMed Web of Science ®Google Scholar
• Nishida M, Nagata K, Hachimori Y, et al. Novel recognition mode between Vav and Grb2 SH3 domains. EMBO J 2001;20:2995-3007
   PubMed Web of Science ®Google Scholar
• Tari A, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun 1997;235:383-8
   PubMed Web of Science ®Google Scholar
• Tari A, Hung MC, Li K, et al. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 1999;18:1325-32
   PubMed Web of Science ®Google Scholar
• Lim SJ, Lopez-Berestein G, Hung MC, et al. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene 2000;19:6271-6
   PubMed Web of Science ®Google Scholar
• Zang XP, Siwak DR, Nguyen TX, et al. KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis 2004;21:437-43
   PubMed Web of Science ®Google Scholar
• Lin F, Monaco G, Sun T, et al. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 2001;20:1873-81
   PubMed Web of Science ®Google Scholar
• Carver K, Ming X, Juliano RL. Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions. Mol Ther Nucleic Acids 2014;3:e153
   PubMedGoogle Scholar
• Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled Phase IIb study. Neuro Oncol 2011;13:132-42
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a Phase I, randomised, first-in-man study. Lancet Neurol 2013;12:435-42
   PubMed Web of Science ®Google Scholar
• Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013;31:638-46
   PubMed Web of Science ®Google Scholar
• Lu JJ, Langer R, Chen J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm 2009;6:763-71
   PubMed Web of Science ®Google Scholar
• Ming X, Sato K, Juliano RL. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release 2011;153:83-92
   PubMed Web of Science ®Google Scholar
• Ming X, Carver K, Fisher M, et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res 2013;41:3673-87
   PubMed Web of Science ®Google Scholar
• Sahay G, Querbes W, Alabi C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013;31:653-8
   PubMed Web of Science ®Google Scholar